


SWAG Cancer Alliance - Colorectal SACT regimen count by initiating trust – Dec 2022-Nov 2023

Key:

Total count of regimens with activity in selected date period, by trust and regimen



XELOX (Capecitabine & Oxaliplatin)

Capecitabine

FOLFIRI/Irinotecan Modified de Gramont

XELIRI (Capecitabine & Irinotecan)

FOLFOX/Oxaliplatin Modified de Gramont

Lonsurf

FOLFOXIRI

Fluorouracil

Pembrolizumab

Cetuximab & Encorafenib

Panitumumab+XELIRI or FOLFIRI

Panitumumab+XELOX or FOLFOX

Cetuximab + FOLFIRI or XELIRI

Cetuximab + FOLFOX

Percentage of all colorectal regimens administered at trust

Trust	XELOX	Cape	FOLF-IRI	XELIRI	FOLFOX	Lonsurf	FOLF-OXIRI	5FU	Pembro	Cetux/Encor	Pani+ FOLFIRI	Pani+ XELIRI	Pani+ FOLFOX	Pani+ XELOX	Cetux+ FOLFIRI	Cetux+ XELIRI	Cetux+ FOLFOX	Bev reg
Glos	27.7%	14.3%	6.6%	11.0%	9.1%	7.1%	0%	5.5%	2.4%	1.6%	0.8%	4.1%	1.1%	1.6%	0.8%	4.1%	0%	2%
UHBW	36.6%	19.1%	9.4%	0%	0.9%	6.1%	7.0%	0.2%	5.3%	2.9%	3.7%	0%	1.5%	0%	0%	0%	0%	0%
Somer-set	30.2%	20.0%	20.0%	0%	11.4%	1.5%	0.3%	0.6%	3.4%	5.5%	3.1%	0%	0.9%	0%	0.3%	0%	0%	0%
RUH	38.6%	11.5%	19.9%	0%	10.9%	5.0%	1.2%	0%	1.9%	2.2%	0.3%	0%	0%	0%	4.7%	0%	1.9%	0%